Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer

WEI-WU CHENHsiao, WenWenHsiaoDai, Ming-ShenMing-ShenDaiCHING-HUNG LINDWANG-YING CHANGI-CHUN CHENMING-YANG WANGChang, Shu-HanShu-HanChangHuang, Shu-MinShu-MinHuangANN-LII CHENGWu, Ko-WenKo-WenWuTan, Kien ThiamKien ThiamTanYEN-SHEN LU2023-07-142023-07-142023-06-2101676806https://scholars.lib.ntu.edu.tw/handle/123456789/633603How to factor both tumor burden and oncogenic genomic mutations as variables to predict the outcome of endocrine-based therapy (ET) in ER-positive/HER2-negative metastatic breast cancer patients (MBC) remains to be explored.enBreast cancer; Cell-free tumor DNA; Endocrine receptor; Liquid biopsy[SDGs]SDG3Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancerjournal article10.1007/s10549-023-06967-3373446602-s2.0-85162272995https://api.elsevier.com/content/abstract/scopus_id/85162272995